Opioid settlement with OxyContin maker Purdue and Sackler family could end years of legal battles
Read Original Source
Jen Trejo holds a photo of her son Christopher as she is comforted outside the Supreme Court Dec. 4, 2023, in Washington. (AP Photo/Stephanie Scarbrough, File) NEW YORK (AP) — A federal bankruptcy court judge on Friday said he will approve OxyContin-maker Purdue Pharma’s latest deal to settle thousands of lawsuits over the toll of opioids that includes some money for thousands of victims of the epidemic. The deal overseen by U.S.
AI Summary
Main Idea: A federal bankruptcy judge said he will approve Purdue Pharma’s new opioid settlement, which would make the Sackler family pay up to $7 billion and could end years of legal fights.
Key Points:
- The deal replaces an earlier settlement the U.S. Supreme Court rejected because it gave the Sacklers broad protection from future lawsuits.
- The agreement would give about $850 million to people harmed by Purdue’s opioids, including more than $100 million for children born with opioid withdrawal.
- Purdue would give up family ownership, change its name to Knoa Pharma, and put future profits toward fighting the opioid crisis.
- Most state and local governments involved support the plan, and very few individual victims voted against it.
Impact on the People
Negative Impact
The settlement may not fully help many opioid victims, and some families may still get little or no money after years of harm.
Positive Impact
Purdue Pharma and the Sackler family would pay billions, sending money to states and some victims to help fight the opioid crisis.
How did each entity affect people?
Rate how each entity in this article affected the American people.
- Primary:Purdue Pharmacompany
- Primary:Sackler familyperson
- Major:Knoa Pharmacompany
Candidate Entities9 candidates · 5 weighted vote min · 70% decision
- Purdue PharmacompanyPrimaryEvaluated
Central company in the settlement and bankruptcy deal, responsible for OxyContin and the litigation at issue.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Sackler familypersonPrimaryEvaluated
Family owners of Purdue Pharma and a central focus because their contribution and liability are key to the.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Knoa PharmacompanyMajorEvaluated
The planned new name for Purdue Pharma, central to the restructuring terms.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Supreme Court of the United Statesgovernment agency or bodyMajorAI selected
Its rejection of the previous Purdue settlement is a central legal turning point in the story.
Include 0 (0%)Ignore 0 (0%)5 to threshold - U.S. Bankruptcy Judge Sean LanepersonMajorAI selected
The judge deciding whether to approve the bankruptcy settlement is a major active figure in the article.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Department of Justicegovernment agency or bodyContextCandidate
Mentioned in relation to the case and prior opioid settlement proceedings, but not a central actor in this.
Include 0 (0%)Ignore 0 (0%)5 to threshold - OxyContinbrand / productContextCandidate
The branded opioid product tied to Purdue Pharma’s litigation and settlement, though it is not an accountable actor.
Include 0 (0%)Ignore 0 (0%)5 to threshold
Comments 0
Comments here are the same thread shown when this article appears in The Pulse.
No comments on this article yet.
Sign in to comment